MetaCap

Disc Medicine Inc. (IRON)

NASDAQ: IRONHealth CareBiotechnology: Pharmaceutical PreparationsUSD

75.14-0.97 (-1.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRON stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$6.34
52-week range
40.00 – 99.50
Day range
74.54 – 77.01
Volume / Avg
561.64K / 951.56K
Beta
—

52-week range

$40.00$99.50

IRON stock today

Disc Medicine (IRON) closed at $75.14 on Nov 20, down 1.27% (-$0.97), versus the S&P 500's 3.70% decline. At this level, IRON sits in the middle of its 52-week range of $40.00 to $99.50: 24.5% below the high, set on Dec 8, 2025 and 87.9% above the low. IRON is down 5.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 18.9%.

Disc Medicine has posted a net loss over the last twelve months (EPS of -$6.34), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Disc Medicine

Company profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. John D. Quisel Esq., J.D., Ph.D.
Headquarters
Watertown, MA
Employees
173

Financial highlights

Full financials

Disc Medicine reported a net loss of $212.2 million, compared with a loss of $109.4 million a year earlier. Diluted earnings per share came in at -$6.01.

Disc Medicine annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-212.18M$-109.36M$-76.43M$-46.83M$-35.97M
EPS (diluted)$-6.01$-3.96$-3.42$-45.05$-40.95

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$127.69+69.94%

  • Strong buy 1
  • Buy 12
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $104.00High $170.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.53 vs $-1.65
Surprise
+7.27%

IRON news

All IRON news

Disc Medicine peers

Health Care sector
IRON peer companies
CompanyPrice% ChgMarket capCompare
PBLSParabilis Medicines Inc.27.44-0.67%$3.44Bvs IRON
ELVNEnliven Therapeutics Inc.46.53+0.26%$3.42Bvs IRON
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs IRON
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs IRON
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs IRON
XENEXenon Pharmaceuticals Inc.37.04-1.38%$3.64Bvs IRON
OGNOrganon & Co.13.89-0.14%$3.65Bvs IRON
TNGXTango Therapeutics Inc.21.73-4.32%$3.68Bvs IRON

Indexes, lists and sector

Disc Medicine stock FAQ

What is Disc Medicine's stock price today?

IRON last traded at $75.14 as of Nov 20, 4:00 PM EST, down 1.27% on the day. Prices are delayed at least 15 minutes.

Does Disc Medicine pay a dividend?

No. Disc Medicine does not currently pay a regular cash dividend.

Who is Disc Medicine's CEO?

Dr. John D. Quisel Esq., J.D., Ph.D. is the chief executive officer of Disc Medicine Inc., which has about 173 employees.

Has IRON ever split its stock?

Yes. The most recent IRON stock split was a 1-for-30 split on Dec 30, 2022.

What is the IRON 52-week high?

The 52-week high for IRON is $99.50 and the 52-week low is $40.00. The stock is currently 24.5% below its high.

Compare IRON